Clinical Context
A typical patient is an adult diagnosed with relapsed or refractory acute promyelocytic leukemia (APL) presenting to an outpatient oncology infusion center or inpatient hematology/oncology unit for administration of J9017 (arsenic trioxide). The clinical workflow begins with hematology/oncology evaluation, review of baseline labs (complete blood count, comprehensive metabolic panel including electrolytes, magnesium, calcium, and hepatic function), and baseline electrocardiogram (ECG) to assess QTc. Vascular access is confirmed (peripheral IV or central venous catheter) and premail medications (antiemetics, electrolyte repletion) are administered as needed. The pharmacy compounds arsenic trioxide per protocol and documents lot and dose; the infusion nurse verifies patient identity, allergy status, and consent. The drug is infused over the institution-specified time with continuous monitoring for cardiac arrhythmia, fluid shifts, and infusion reactions; serial laboratory monitoring and ECGs are obtained during induction and consolidation phases per oncology protocol. Dose adjustments or treatment holds are documented if severe toxicity, QTc prolongation, or organ dysfunction occurs. Billing uses J9017 per milligram dispensed with appropriate site-of-service designation for outpatient infusion centers, hospital outpatient departments, or inpatient care depending on the treatment setting.